Ainos [AIMD] - Last Close: $1.73
This tiny stock is gaining ground after regaining compliance with Nasdaq’s $1 minimum bid price requirement.
Ainos announced it regained compliance with the rule earlier this week, but the market’s reaction was muted at first.
Shares are down 15.6% over the past five days, despite the good news from Nasdaq, but prices are rebounding in today’s premarket.
AIMD is currently leading the premarket with a 154.3% gain on over 10 million shares traded.
My Take: AIMD’s rally could be the result of targeted buying of its shares, since the stock has a very small float at just $8 million.
Dermata Therapeutics [DRMA] - Last Close: $0.6099
An after-hours announcement of a new patent is skyrocketing this tiny biotech stock ahead of today’s opening bell.
Yesterday, Dermata Therapeutics said it was issued a new patent in Japan for its DMT410 program to treat hyperhidrosis.
The program utilizes the company’s Spongilla technology to deliver a therapeutic dose of botulinum toxin to treat the condition.
CEO Gerry Proehl said in a press release, “We are excited about the opportunities the DMT410 program can bring to patients.”
DRMA is up 63.9% on news of the patent, and nearly 7 million shares have been traded in the premarket so far.
My Take: DRMA has had a rough run over the past couple of months, but it seems to have found strong support at the 60-cents mark. It could also find support at $1 if it can hold its gains through the close.
Safe and Green Development [SGD] - Last Close: $1.36
This company just provided an update on a previously announced letter of intent to acquire Majestic World Holdings.
In the press release, the company said it plans to complete the acquisition by the end of Q1.
"The successful BETA run earlier in 2023 has given us the confidence to move forward with a complete acquisition of the XENE Platform,” CEO David Villareal said in the press release.
SGD is a top mover with a 66.1% gain on more than 11 million shares traded.
My Take: SGD has had a pretty unimpressive run since the start of December, but this deal could give the stock some momentum.
Immunic [IMUX] - Last Close: $1.43
This under-the-radar biotech stock is getting a boost after announcing a new private placement worth up to $240 million.
Early this moning, Immunic said it entered into a securities purchase deal with select accredited investors in a three-tranche offering.
The first tranche is an upfront payment of $80 million at $1.43 per share, expected to close on January 8th, 2024.
Additional payments will be triggered down the road if the company acheives certain clinical and developmental milestones.
IMUX is up 23.0% on roughly 7.5 million shares traded today.
My Take: IMUX has been up-trending since bottoming out at about $1 apiece in November, and this catalyst could put more gas in its tank.